Dr. Schenk, a hematology and oncology specialist, provides insight into factors that may help doctors determine whether patients with lung cancer should be retested over the course of their disease.
Dr. Erin Schenk is an assistant professor in the division of medical oncology at the University of Colorado Anschutz Medical Center. Learn more about Dr. Schenk and her lung cancer research, here.
In our practice here at the University of Colorado, we frequently re-biopsy patients who have a molecular abnormality within their cancer that we’ve been treating with a pill medicine. The reason we do that is it helps us better understand why the cancer cells became resistant to the targeted therapy we had been giving them.
And occasionally, we can do other targeted therapies or other pill medicines to target the cancer cells. So, it helps us get more information in terms of why the cancer became resistance, and occasionally, we’re able to use additional oral therapies to target the cancer cells and those mechanisms of resistance.